PAHC on Nasdaq

PHIBRO ANIMAL HEALTH CORP

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

$1.5BRevenue, fiscal 20262
$99.7MNet income, fiscal 20262

Compare with Alkermes, PTC Therapeutics or Indivior, or pick any stock.

  • TickerPAHC on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersTeaneck, New Jersey1
  • Incorporated inDE3
  • Business addressGlenpointe Centre East, 3Rd Floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, Nj 076663
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. We market approximately 790 product lines in approximately 90 countries to approximately 4,800 customers. We develop, manufacture and market a broad range of products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. Our products help prevent, control and treat diseases and support nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products either directly to integrated poultry, cattle and swine producers or through animal feed manufacturers, wholesalers, distributo…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

33.8%Gross margin2
12.8%Operating margin2
6.6%Net margin2
17.1%Revenue growth, 20262
25.9%Return on equity2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Medicated Feed Additives and Others brought in 53% of the revenue PHIBRO ANIMAL HEALTH CORP broke down this way in fiscal 2026.

  1. Medicated Feed Additives and Others$810.7M253%up 25% from 2025
  2. Mineral Nutrition$282.3M219%up 11% from 2025
  3. Nutritional Specialties$195.1M213%up 9% from 2025
  4. Vaccines$156.4M210%up 14% from 2025
  5. Performance Products$73.5M25%down 8% from 2025
Products and services by year
Products and services202420252026
Medicated Feed Additives and Others$421.0M$646.4M$810.7M
Mineral Nutrition$243.7M$253.2M$282.3M
Nutritional Specialties$164.7M$179.3M$195.1M
Vaccines$120.9M$137.2M$156.4M
Performance Products$67.5M$80.2M$73.5M

Business segments

Animal Health brought in 77% of the revenue PHIBRO ANIMAL HEALTH CORP broke down this way in fiscal 2026.

  1. Animal Health$1.2B277%up 21% from 2025
  2. Mineral Nutrition$282.3M219%up 11% from 2025
  3. Performance Products$73.5M25%down 8% from 2025
Business segments by year
Business segments202420252026
Animal Health$706.5M$962.8M$1.2B
Mineral Nutrition$243.7M$253.2M$282.3M
Performance Products$67.5M$80.2M$73.5M

Regions

United States brought in 58% of the revenue PHIBRO ANIMAL HEALTH CORP broke down this way in fiscal 2026.

  1. United States$877.1M258%up 19% from 2025
  2. Latin America and Canada$340.7M222%up 14% from 2025
  3. EMEA$187.9M212%up 17% from 2025
  4. Asia Pacific$112.4M27%up 15% from 2025
Regions by year
Regions202420252026
United States$584.8M$739.9M$877.1M
Latin America and Canada$247.7M$298.6M$340.7M
EMEA$122.0M$160.2M$187.9M
Asia Pacific$63.2M$97.4M$112.4M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue66¢$1.0B
  • Research and development2¢$24.6M
  • Selling, general and admin21¢$318.1M
  • Other costs2¢$32.5M
  • Income tax2¢$37.6M
  • Profit7¢$99.7M

Out of $1.5B in revenue.2

Where each dollar of operating cash went, fiscal 2026

  • Dividends paid28¢$19.5M
  • Kept or used elsewhere72¢$49.5M

Out of $69.0M of cash from operations.2

Financial statements

Revenue567892$1.5B in 2026+83% since 2019
0$500.0M$1.0B$1.5B$2.0B2019: $828.0M$828.0M20192020: $800.4M$800.4M2020−3%2021: $833.4M$833.4M2021+4%2022: $942.3M$942.3M2022+13%2023: $977.9M$977.9M2023+4%2024: $1.0B$1.0B2024+4%2025: $1.3B$1.3B2025+27%2026: $1.5B$1.5B2026+17%
Gross profit567892$512.5M in 2026+94% since 2019
0$200.0M$400.0M$600.0M2019: $264.6M$264.6M20192020: $256.9M$256.9M2020−3%2021: $271.4M$271.4M2021+6%2022: $285.4M$285.4M2022+5%2023: $298.2M$298.2M2023+4%2024: $313.1M$313.1M2024+5%2025: $399.9M$399.9M2025+28%2026: $512.5M$512.5M2026+28%
Operating income567892$194.4M in 2026+134% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $83.2M$83.2M20192020: $69.2M$69.2M2020−17%2021: $74.9M$74.9M2021+8%2022: $79.0M$79.0M2022+6%2023: $71.8M$71.8M2023−9%2024: $53.3M$53.3M2024−26%2025: $110.5M$110.5M2025+107%2026: $194.4M$194.4M2026+76%
Net income567892$99.7M in 2026+82% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $54.7M$54.7M20192020: $33.6M$33.6M2020−39%2021: $54.4M$54.4M2021+62%2022: $49.2M$49.2M2022−10%2023: $32.6M$32.6M2023−34%2024: $2.4M$2.4M2024−93%2025: $48.3M$48.3M2025+1898%2026: $99.7M$99.7M2026+107%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2026-06-302025-06-302024-06-30
Net sales$1.5B$1.3B$1.0B
Cost of goods sold$1.0B$896.3M$704.6M
Gross profit$512.5M$399.9M$313.1M
Selling, general and administrative expenses$318.1M$289.5M$259.8M
Operating income$194.4M$110.5M$53.3M
Interest expense, net$44.4M$34.6M$18.5M
Foreign currency losses, net$12.6M$7.9M$23.9M
Income before income taxes$137.3M$68.0M$10.9M
Provision for income taxes$37.6M$19.7M$8.5M
Net income$99.7M$48.3M$2.4M
Basic (in dollars per share)$2.46$1.19$0.06
Diluted (in dollars per share)$2.43$1.19$0.06
Basic (in shares)40.5M shares40.5M shares40.5M shares
Diluted (in shares)41.0M shares40.7M shares40.5M shares

Compare PHIBRO ANIMAL HEALTH CORP with another company

Leadership

Who has led PHIBRO ANIMAL HEALTH CORP, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jack Bendheim2014–2026
  2. Daniel M. Bendheim2026–now

Chair

  1. Jack Bendheim2026–now

President

  1. Jack Bendheim2014–2019
  2. Robin Aukerman2019
  3. Daniel M. Bendheim2026–now

Chief financial officer

  1. Richard G. Johnson2014–2017
  2. Damian Finio2020
  3. Glenn David2024–now

Chief operating officer

  1. Gerald K. Carlson2014–2016
201520202025
Board members and other officers (20)

Former names

  • PHILIPP BROTHERS CHEMICALS INCDec 14, 1998 to May 14, 20033

Timeline

  1. Jul 2, 2026New chief executive Daniel M. Bendheim becomes CEO14
  2. Apr 10, 2014New chief executive Jack Bendheim becomes CEO15

Filings

225 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 73 insider forms, 38 large holders, 34 other. The latest 20:

  1. Sep 18, 2026ARS EDGAR
  2. Sep 18, 2026DEFA14A EDGAR
  3. Sep 18, 2026DEF 14A EDGAR
  4. Sep 17, 20264/A OWNERSHIP DOCUMENT EDGAR
  5. Sep 17, 20264/A OWNERSHIP DOCUMENT EDGAR
  6. Sep 16, 2026144 EDGAR
  7. Aug 26, 20268-K EDGAR
  8. Aug 26, 202610-K EDGAR
  9. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  10. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  15. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Aug 10, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Aug 6, 20264 OWNERSHIP DOCUMENT EDGAR
  18. Aug 6, 20264 OWNERSHIP DOCUMENT EDGAR
  19. Aug 6, 20264 OWNERSHIP DOCUMENT EDGAR
  20. Aug 6, 20264 OWNERSHIP DOCUMENT EDGAR

The 225 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

77 open-market trades by officers, directors and large owners since October 2021: 3 buys and 74 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 29, 2026CORCORAN E THOMASDirectorBuy10,000$31.77$317.7KForm 4
May 7, 2026BENDHEIM JACKExecutive ChairmanSale4,528$48.49$219.6KForm 4
May 6, 2026BENDHEIM JACKExecutive ChairmanSale7,040$57.37$403.9KForm 4
May 5, 2026BENDHEIM JACKExecutive ChairmanSale7,040$55.80$392.8KForm 4
Apr 30, 2026BENDHEIM JACKExecutive ChairmanSale7,040$52.77$371.5KForm 4
Apr 29, 2026BENDHEIM JACKExecutive ChairmanSale7,040$52.92$372.6KForm 4
Apr 28, 2026BENDHEIM JACKExecutive ChairmanSale7,040$55.91$393.6KForm 4
Apr 23, 2026BENDHEIM JACKExecutive ChairmanSale7,040$54.10$380.9KForm 4
Apr 22, 2026BENDHEIM JACKExecutive ChairmanSale7,040$54.29$382.2KForm 4
Apr 21, 2026BENDHEIM JACKExecutive ChairmanSale7,040$55.98$394.1KForm 4
Apr 16, 2026BFI Co., LLC10% ownerSale7,040$54.64$384.7KForm 4
Apr 15, 2026BFI Co., LLC10% ownerSale7,040$56.96$401.0KForm 4
Apr 14, 2026BFI Co., LLC10% ownerSale7,040$59.08$415.9KForm 4
Mar 31, 2026BENDHEIM JACKExecutive ChairmanSale7,040$53.90$379.5KForm 4
Mar 30, 2026BENDHEIM JACKExecutive ChairmanSale7,040$53.61$377.4KForm 4
Mar 26, 2026BENDHEIM JACKExecutive ChairmanSale7,040$56.81$399.9KForm 4
Mar 25, 2026BENDHEIM JACKExecutive ChairmanSale7,040$55.91$393.6KForm 4
Mar 24, 2026BENDHEIM JACKExecutive ChairmanSale7,040$52.93$372.6KForm 4
Mar 19, 2026BENDHEIM JACKExecutive ChairmanSale7,040$52.52$369.7KForm 4
Mar 18, 2026BENDHEIM JACKExecutive ChairmanSale10,560$52.68$556.3KForm 4

All 77 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.3,219,040$101.1M0.0%−34,808
Fmr LLC3,160,281$99.2M0.0%+987,155
State Street Corp1,038,382$32.6M0.0%+88,349
Millennium Management LLC936,701$29.4M0.0%+880,882
Vanguard Capital Management LLC923,318$29.0M0.0%+32,035
Geode Capital Management, LLC657,350$20.6M0.0%+52,702
Dimensional Fund Advisors LP531,087$16.7M0.0%+23,235
Vanguard Portfolio Management LLC508,486$16.0M0.0%+18,144
Renaissance Technologies LLC480,500$15.1M0.0%−96,235
CastleKnight Management LP461,322$14.5M0.5%+385,427
Morgan Stanley412,634$13.0M0.0%+21,447
Dana Investment Advisors, Inc.387,867$12.2M0.3%+100,143
Invesco Ltd.336,329$10.6M0.0%+5,352
Nuveen, LLC314,079$9.9M0.0%−141,812
Oberweis Asset Management Inc/311,100$9.8M0.2%+34,000
Ranger Investment Management, L.P.292,410$9.2M0.6%+13,935
Charles Schwab Investment Management Inc260,861$8.2M0.0%−3,401
Bank of New York Mellon Corp254,380$8.0M0.0%+24,389
Allspring Global Investments Holdings, LLC254,234$8.0M0.0%−31,938
Northern Trust Corp237,528$7.5M0.0%+18,127
Hennessy Advisors Inc221,700$7.0M0.2%New
Crawford Investment Counsel Inc205,256$6.4M0.1%+17,750
Globeflex Capital L P189,224$5.9M0.8%−20,815
Russell Investments Group, Ltd.183,563$5.8M0.0%−9,873
Qube Research & Technologies Ltd181,127$5.7M0.0%−27,322

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47